JPT has a work force of >150 highly trained and skilled employees. 30 of our co-workers hold a university degree and 20 have a PhD in natural sciences. Over the last 15 years our team has built a substantial know-how in all areas of peptide applications ranging from antigen discovery and immune monitoring to proteomics and immunotherapy development.
Dr. Holger Wenschuh (Managing Director)
Dr. Holger Wenschuh has been Managing Director at JPT Peptide Technologies since 2004. Before, he served as Business Unit Manager at Jerini AG and Managing Director at Chemotopix GmbH. Dr. Wenschuh studied Chemistry at the Friedrich-Schiller-University in Jena, Germany, and obtained his PhD in Organic Chemistry at the Institute of Molecular Pharmacology in Berlin, Germany. He worked at the University of Massachusetts and Perseptive Biosystems, USA and from 1995 to 1997, headed the Peptide Unit at the Max-Planck-Institute of Infection Biology in Berlin.
Dr. Wenschuh is author and co-author of numerous publications, co-inventor on several patents and editorial board member of the International Journal of Peptide Research and Therapeutics.
Sean Marett (Managing Director)
Sean Marett has 30 years of international experience in the management of operations, sales and marketing licensing, M&A and new product development.
He has worked for large pharmaceutical companies such as GSK and Pfizer and done contract research, development and manufacturing for companies such as Evotec and NextPharma. He has successfully executed a number of licensing transactions with large pharmaceutical companies, completed large pharmaceutical service deals and negotiated several M&A transactions. Sean Marett is non-executive director of KWS BioTest Ltd and a member of the investment committee of Mann BioInvest Ltd.
Dr. Sierk Poetting (Managing Director)
Dr. Sierk Poetting holds a Master of Science in Optical Sciences from the University of Arizona and a Ph.D. in Physics from the Ludwig-Maximilians-University in Munich.
From 2012 to August 2014 he worked for Novartis and served as Vice President and Chief Financial Officer for the Sandoz Division in North America.
Afterwards he took over the position as Chief Financial Officer and Chief Operating Officer at BioNTech which is now a Nasdaq-listed and one of the biggest European biotech-companies.